

FIG. 1A and FIG. 1B Hybrid ImmunoCapture (HIC) Assay




□ = without 2-thio PAF substrate

FIG. 2: Plasma Lp-PLA2 Activity in HIC-ThioPAF Assay (2c10 as capturing mAb)




☐ = without 2-thio PAF substrate

FIG. 3: Plasma Lp-PLA2 Activity in HIC-ThioPAF Assay (B200.1 as capturing mAb)



OD


FIG. 4: Plasma Lp-PLA2 Activity in HIC-ThioPAF Assay (B501.1 as capturing mAb)



○ = with 2-thio PAF substrate

☐ = without 2-thio PAF substrate

FIG. 5: Plasma Lp-PLA2 Activity in HIC-MNP Assay (2c10 as capturing mAb)




○ = with 1-myristoyl-2-(4-nitrophenylsuccinyl) phosphatidylcholine substrate (MNP) = without 1-myristoyl-2-(4-nitrophenylsuccinyl) phosphatidylcholine substrate


٠:

□ = without 2-thio PAF substrate

FIG. 6: Plasma Lp-PLA2 Activity In Commercial ThioPAF Assay




ThioPAF Assay, with DTNB but w/o substrate added FIG. 7: Plasma sample background in Improved



○ = without 2-thio PAF substrate; with DTNB added





○ = with 2-thio PAF substrate

□ = without 2-thio PAF substrate